156 related articles for article (PubMed ID: 15496148)
1. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect.
Yu L; Border WA; Anderson I; McCourt M; Huang Y; Noble NA
Kidney Int; 2004 Nov; 66(5):1774-84. PubMed ID: 15496148
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis.
Peters H; Border WA; Noble NA
Kidney Int; 2000 Apr; 57(4):1493-501. PubMed ID: 10760085
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis.
Peters H; Rückert M; Gaedeke J; Liefeldt L; Ketteler M; Sharma AM; Neumayer HH
J Hypertens; 2003 Apr; 21(4):771-80. PubMed ID: 12658024
[TBL] [Abstract][Full Text] [Related]
4. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade.
Peters H; Border WA; Noble NA
Kidney Int; 1998 Nov; 54(5):1570-80. PubMed ID: 9844133
[TBL] [Abstract][Full Text] [Related]
5. Effect of combination therapy with enalapril and the TGF-beta antagonist 1D11 in unilateral ureteral obstruction.
El Chaar M; Chen J; Seshan SV; Jha S; Richardson I; Ledbetter SR; Vaughan ED; Poppas DP; Felsen D
Am J Physiol Renal Physiol; 2007 Apr; 292(4):F1291-301. PubMed ID: 17164399
[TBL] [Abstract][Full Text] [Related]
6. Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis.
Zhang J; Gu C; Noble NA; Border WA; Huang Y
Am J Physiol Renal Physiol; 2011 Oct; 301(4):F723-32. PubMed ID: 21795644
[TBL] [Abstract][Full Text] [Related]
7. Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis.
Zhang J; Noble NA; Border WA; Huang Y
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F579-88. PubMed ID: 20032116
[TBL] [Abstract][Full Text] [Related]
8. An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease.
Gu C; Zhang J; Noble NA; Peng XR; Huang Y
Am J Physiol Renal Physiol; 2016 Nov; 311(5):F852-F863. PubMed ID: 27511457
[TBL] [Abstract][Full Text] [Related]
9. Platelet inhibition limits TGF-beta overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis.
Peters H; Eisenberg R; Daig U; Liefeldt L; Westenfeld R; Gaedeke J; Krämer S; Neumayer HH
Kidney Int; 2004 Jun; 65(6):2238-48. PubMed ID: 15149337
[TBL] [Abstract][Full Text] [Related]
10. Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis.
Peters H; Border WA; Noble NA
Kidney Int; 2000 Mar; 57(3):992-1001. PubMed ID: 10720952
[TBL] [Abstract][Full Text] [Related]
11. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.
Huang Y; Wongamorntham S; Kasting J; McQuillan D; Owens RT; Yu L; Noble NA; Border W
Kidney Int; 2006 Jan; 69(1):105-13. PubMed ID: 16374430
[TBL] [Abstract][Full Text] [Related]
12. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.
Oikawa T; Freeman M; Lo W; Vaughan DE; Fogo A
Kidney Int; 1997 Jan; 51(1):164-72. PubMed ID: 8995730
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.
Shihab FS; Bennett WM; Tanner AM; Andoh TF
Kidney Int; 1997 Sep; 52(3):660-73. PubMed ID: 9291185
[TBL] [Abstract][Full Text] [Related]
14. NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis.
Peters H; Daig U; Martini S; Rückert M; Schäper F; Liefeldt L; Krämer S; Neumayer HH
Kidney Int; 2003 Aug; 64(2):509-18. PubMed ID: 12846746
[TBL] [Abstract][Full Text] [Related]
15. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.
Zoja C; Abbate M; Corna D; Capitanio M; Donadelli R; Bruzzi I; Oldroyd S; Benigni A; Remuzzi G
Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682
[TBL] [Abstract][Full Text] [Related]
17. [Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure].
Ciechanowicz A
Ann Acad Med Stetin; 1999; Suppl 52():1-93. PubMed ID: 10589103
[TBL] [Abstract][Full Text] [Related]
18. [Effect of enalapril on the expression of TGF-beta1, p-Smad2/3 and Smad7 in renal interstitial fibrosis in rats].
Ning W; Tao L; Liu C; Sun J; Xiao Y; Hu J; Chen J; Zheng X; Wang W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 34(1):27-34. PubMed ID: 19197123
[TBL] [Abstract][Full Text] [Related]
19. Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis.
Gaedeke J; Boehler T; Budde K; Neumayer HH; Peters H
Nephrol Dial Transplant; 2005 Feb; 20(2):319-28. PubMed ID: 15673690
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
Krämer S; Loof T; Martini S; Rückert M; Wang Y; Böhler T; Shimizu F; Kawachi H; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
